Search clinical trials for: Rubella vaccine safety

Total 50363 results

Shanghai Institute Of Biological Products
Victoria Biomedical Research Institute

Not yet recruiting

Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months

Measles-Mumps-Rubella
GlaxoSmithKline
Kwame Nkrumah University of Science and Technology; European & Developing Countries... and other collaborators

Recruiting

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

Salmonella Infections

Ghana
Shanghai Municipal Center for Disease Control and...
China National Biotec Group Company Limited

Not yet recruiting

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines

Measles | Rubella | Mumps | Varicella | SARS-CoV-2 Infection

China
International Centre for Diarrhoeal Disease Research...
Centers for Disease Control and Prevention

Not yet recruiting

Co-administration Study of OCV, TCV and MR

Measles | Rubella | Cholera | Typhoid
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants

Diarrhoea

Belgium, Kenya
University of Oxford
Malaria Research and Training Center, Bamako, Mali

Active, not recruiting

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Malaria

Mali, United Kingdom
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Measles; Mumps; Rubella; Chickenpox

United States, Taiwan, Spain, Argentina, Turkey, Colombia, Puerto Rico, Latvia, Chile
GlaxoSmithKline
IQVIA, USA

Active, not recruiting

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Chickenpox

Taiwan, Poland, United States, Estonia, Puerto Rico, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (MET55)

Healthy Volunteers (Meningococcal Infection)

India, South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET41)

Healthy Volunteers (Meningococcal Infection)

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico (MET33)

Healthy Volunteers (Meningococcal Infection)

Mexico, Russian Federation
Shanghai Institute Of Biological Products

Completed

Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live

Vaccine | Immunotoxicity

China
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) (PNEU-PED-EU-2)

Pneumococcal Infections

Denmark, Finland, Italy, Norway, Sweden
Micron Biomedical, Inc
Medical Research Council; Centers for Disease Control and Prevention

Completed

Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial

Healthy | Measles | Rubella | Vaccination

Gambia
Zhejiang Provincial Center for Disease Control...

Active, not recruiting

The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine

Measles | Rubella | Mumps | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18

China
Themis Bioscience GmbH

Completed

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine (MV-CHIK-202)

Chikungunya Virus Infection

Austria, Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Malaria | Malaria Vaccines

Ghana
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine

Mumps

China
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Measles; Mumps; Rubella | Measles-Mumps-Rubella Vaccine

United States, Finland, Taiwan, Estonia, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Measles | Rubella | Mumps | Measles-Mumps-Rubella Vaccine

Finland, Thailand, United States, Spain, Czechia, Puerto Rico, Malaysia
PATH
Syneos Health; Research Institute for Tropical Medicine; DF/Net Research, Inc.

Completed

Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine

Encephalitis, Japanese | Measles | Rubella | Mumps

Philippines
The Immunobiological Technology Institute (Bio-Manguinhos)...
Oswaldo Cruz Institute

Completed

Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella (BIOMR)

Measles | Rubella

Brazil
GlaxoSmithKline

Completed

Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

Measles | Rubella | Mumps | Measles-Mumps-Rubella Vaccine

United States, Puerto Rico
PT Bio Farma

Completed

Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)

Measles | Congenital Rubella Infection

Indonesia
GlaxoSmithKline

Completed

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Measles | Rubella | Mumps

United States, Finland, Estonia, Spain, Mexico, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Measles-Mumps-Rubella

Taiwan, United States, Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Measles | Rubella | Mumps | Varicella

Taiwan, Singapore
PT Bio Farma

Completed

Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children

Safety Issues | Immunogenicity

Indonesia
Merck Sharp & Dohme LLC

Completed

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Measles | Hepatitis A | Rubella | Mumps | Chickenpox
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)

Measles | Rubella | Mumps | Varicella
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Measles | Rubella | Mumps | Varicella

United States
Novartis Vaccines

Completed

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

Meningococcal Meningitis

Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

Tetanus | Diphtheria | Acellular Pertussis

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children

Measles | Rubella | Mumps | Varicella

Italy
GlaxoSmithKline

Completed

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Hepatitis A

United States
GlaxoSmithKline

Completed

Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

Measles | Rubella | Mumps | Varicella

India
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

Measles | Rubella | Mumps | Varicella

Korea, Republic of
GlaxoSmithKline
Parexel

Completed

Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

Measles | Rubella | Mumps

United States, Slovakia, Estonia
Merck Sharp & Dohme LLC

Completed

Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)

Varicella
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

Measles | Rubella | Mumps | Varicella
GlaxoSmithKline

Completed

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Mexico
GlaxoSmithKline

Completed

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Measles | Rubella | Mumps | Varicella

Canada, Italy
GlaxoSmithKline

Completed

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Measles | Rubella | Mumps | Varicella

Germany, Italy, France
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Measles | Rubella | Mumps | Varicella

Belgium, Germany, Netherlands
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Measles | Rubella | Mumps | Varicella

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Measles | Rubella | Mumps | Varicella

Finland, Germany, Poland, Greece
GlaxoSmithKline

Completed

Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine

Measles | Rubella | Mumps | Varicella

Germany, Austria

3

Subscribe